This is mainly due to savings and compensation resulting from reorganizations that took place earlier in 2021. We have made progress since transitioning our sales approach to osteoporosis and expect to make continued progress. However, due to lower than expected year-to-date TYMLOS revenue, we've adjusted our full year 2021 TYMLOS revenue forecast to a range of $210 million to $220 million for us the previous forecast of $240 million. We also forecast total company EBITDA to be in a range of $5 million to $15 million loss versus a previous forecast of a positive $10 million.